Logo

Zydus’ Bortezomib Receives the US FDA’s Approval for the Treatment of Cancer

Share this

Zydus’ Bortezomib Receives the US FDA’s Approval for the Treatment of Cancer

Shots:

  • The company has received the US FDA approval to manufacture and market Bortezomib for inj. 3.5 mg/vial (single-dose vial) to be bioequivalent and therapeutically equivalent to the Velcade to treat cancer incl. multiple myeloma and mantle cell lymphoma
  • The drug will be manufactured at Zydus Hospira. The medication works by slowing or stopping cancer cell growth
  • The company has manufacturing and research facilities in five Indian states: Gujarat, Maharashtra, Goa, Himachal Pradesh, and Sikkim along with US and Brazil. Zydus' global business is well-established in regulated markets i.e., the US, EU (France and Spain), and the high-profile markets of Latin America and South Africa

Ref:The Hans India | Image: Zydus

Click here to­ read the full press release 

Senior Editor

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions